1,1-Difluoroethane (DFE) is a halogenated hydrocarbon used as a propellant in products designed
Introduction
Products containing 1,1-difluoroethane (DFE) have been cited with increasing frequency as sources of inhalant exposure in reports from government agencies (1) and organizations involved in inhalant abuse (2) . According to a 2004 SAMSHA survey, 23 million U.S. residents reported that they had abused inhalants and of these, 10% had done so within the last year (3) . Among inhalant abusers, the abuse of duster products rose from 12.6 to 25.4% during the period 2002-2005 (4) . When combined these surveys suggest that abuse of duster products doubled between 2002 and 2005, rising from nearly 2.9 million to 5.8 million US residents.
Inhalation of DFE is reported to produce rapid onset of intoxication and impairment. In addition, abuse of inhalants like DFE has also been reported to cause sudden death (5) (6) (7) (8) .
Deaths have therefore occurred due to DFE's ability to impair cognitive function, which sometimes leads to accidental death, and also due to DFE's inherent cardio-toxicity (9) (10) (11) . In addition, drivers under the influence of inhaled DFE are regularly involved in motor vehicle crashes that have resulted not only in property loss but have also had fatal outcome to passengers, pedestrians and other motorists.
DFE has both central nervous system (CNS) and cardiac effects that were until recently thought to be adequately described by the Meyer-Overton theory, which said that the lipid solubility of volatile agents resulted in alterations to cell membrane integrity allowing unregulated flow of ions (12) (13) (14) . However that theory of volatile chemistry has been largely replaced with the concept that, like other abused drugs, there are specific protein targets for volatile agents and that inhalant induced effects on receptor mediated electrochemistry occur at concentrations that have no effect on membrane integrity (15) (16) (17) .
A primary target for volatile agents such as toluene and 1,1,1-trichloroethane (TCE) is the γ-aminobutyric acid A receptor (GABA A ). By increasing the affinity of the GABA A receptor for the endogenous neurotransmitter γ-aminobutyric acid (GABA) volatile inhalants cause CNS depression, euphoria, and muscular in-coordination (13, 18, 19) . Compounds structurally related to DFE are also believed to sensitize myocardial tissue to endogenous catecholamine leading to potentially fatal arrhythmias (5, 20) . In one study, three of 12 dogs developed cardiac arrhythmias and died following exposure to 0.405 g/L of DFE and 0.008 mg/kg of epinephrine (21) . Although that study demonstrated DFE's cardiotoxic potential, tissue DFE levels were not given. In three postmortem cases where sudden death was attributed to the arrhythmogenic effects of DFE, femoral blood DFE levels were 83.5, 136.3, and 218.1 mg/L (22) . The mechanism of action which leads to arrhythmia and cardiac failure is poorly understood. Recently Jiao et al. (23) reported a decrease in conduction velocity in cardiomyocytes treated with CF 3 Br and epinephrine but not CF 3 Br alone. Their results were not conclusive because they could not exclude alternate toxic mechanisms such as involvement of other ion channels.
Given that DFE exerts toxic effects in two different organ systems it is possible that differences in relative uptake and elimination in these organ systems partly explains some of the observed effects. Although volatile toxins have been shown to act on specific protein targets within the CNS, this does not preclude the possibility that high concentrations of DFE and other solvents also have effects on membrane integrity. Therefore if accumulation of DFE occurs with repeated dosing, effects on membrane integrity might predominate.
Little data exist regarding the relative uptake and elimination of DFE in the different biological compartments. Those studies which have been performed have either used low dose exposures similar to those which might be encountered in the work place or have not conducted chemical analyses on relevant tissues such as brain, heart, and liver (21) . For wellstudied toxins, measured tissue levels may be used to estimate the effects, dose, time, and/or duration of exposure. With respect to DFE, such conclusions are currently not possible.
The purpose of this work was to measure DFE concentrations in different tissue compartments in the rat as a function of time following exposure to levels of DFE consistent with abuse. The protocol examined the uptake, distribution and elimination phases of DFE in different body compartments. Tissues of interest included blood, because of its relevance to postmortem and human performance toxicology, and brain and heart because they are the primary target organ systems for DFE. In addition, because of their importance in toxicology and their high blood perfusion rate, liver and kidney were also collected and analyzed. Upon completion, plots of DFE concentration over time were used to identify the toxicokinetic model that best describes DFE uptake and elimination. Plots also allowed for the reasonable estimation of DFE bioavailability following inhalation exposure and provided the experimental determination of DFE half-life (t ½ ) in blood, brain and heart. Dosed animals were observed for evidence of intoxication in the form of prostration and reduced motor activity. These effects were then correlated to DFE tissue concentrations in CNS (brain), heart, and blood. Particular attention was paid to the relative concentration of DFE in brain and cardiac tissue because of the evidence that the mechanism of action of halogenated hydrocarbons in those systems may be distinct. Therefore differences in the relative uptake and/or concentration in these tissues may be critical to development of toxic effects.
Materials and Methods
Male Sprague-Dawley (SD) rats (300 g) were obtained from Taconic Farms (Germantown, NY). Animals were housed two per cage for two weeks after arrival. The animals had free access to food and water, and were kept on a 12-h light/dark cycle. All protocols were approved by the St. John's University Institutional Animal Care and Use Committee. 600 g of > 98% 1,1-difluoroethane was obtained from Sigma-Aldrich Chemical St. Louis, MO. A Labcrest Flowmeter # 448-225 had been previously obtained. All other apparatus were designed in house.
DFE exposure
The toxicokinetic study was conducted using rats (n = 30), exposed to a fixed amount of DFE. DFE delivery was accomplished using an apparatus ( Figure 1 ) that feed gas to a dynamic exposure chamber large enough to contain two animals (chamber = 2298 cm 3 ). Gas from a 600-g canister of > 98% DFE was passed through a gas regulator equipped with a shut off valve. The regulated shut off valve fed gas to a calibrated gas flow meter set to deliver 20 L/min of DFE. The flow meter controlled gas flow into the exposure chamber. Gas outflow from the chamber was passed into a charcoal filter for safety. Animals were weighed then exposed to 30 s of 20 L/min DFE gas. Sample introduction was controlled precisely by using the shut off valve which allowed instantaneous control of flow. After exposure the chamber was immediately opened and the animals were removed. Animals were sacrificed and tissues were collected at fixed intervals. Groups (n = 3) were sacrificed at 0, 10, 20, 30, 45, 60, 120, 240, 480, and 900 s. Animals were killed by decapitation, using a guillotine. Trunk blood was collected in 20-mL headspace vials which were crimped immediately. Other collected tissues included brain, heart, liver and kidney. After a satisfactory amount of each tissue was collected, it was placed immediately into a 20-mL headspace vial, which was sealed. All specimens were subsequently labeled and stored frozen at -12.8°C.
Analytical
Specimens were analyzed for DFE using an Agilent 6850 gas chromatograph equipped with a 7694 headspace autosampler. The system was fitted with a flame-ionization detector. System calibration and specimen analysis were performed using a previously reported method (24) . Further data analysis was performed using Graph Pad Prism software (v. 4, San Diego, CA).
Prior to analysis the weight of each collected specimen was determined and recorded. Tissue were grouped (all bloods, brains etc) and analyzed for DFE content using the method previously described. After nominal tissue concentrations were determined, samples were corrected for weight and volume before recording final concentrations. Tissue concentrations were plotted against time.
To calculate t ½ of DFE in selected compartments, concentration results were collected from nonlinear regression analysis at points that occurred in the alpha (α), beta (β), and gamma (γ) phases. For the elimination phases multiple points were determined and the results were averaged. Point selection, accomplished by visual inspection of graphs, and toxicokinetic equations are described by 
Medinsky and Valentine (25).
Maximum DFE exposure (Dose Max ) for 320 g male rats was estimated using a respiratory minute volume of 0.21 L/min (26) . Pure DFE at 1 atm contains 2.7 g/L (24) therefore, 30 s of 2.7 g/L DFE = 283 mg or 0.884 mg/g for a 320-g animal assuming 100% absorption.
Total uptake (burden) in each tissue was calculated by taking average tissue concentrations at time 0 (t 0 ) and determining total DFE amounts in each based upon average organ weights of 320-g male Sprague Dawley rats. The blood volume was estimated to be 21.9 mL (27) . Other estimated tissue weights were, brain 2.1 g, heart 1.3 g, liver 8.6 g, and kidneys 2.5 g (28) . Tissue burdens were summed to estimate total body burden. Percent uptake of individual tissue compartments = tissue burden (μg)/Dose Max (μg) · 100. Total percent uptake = total body burden/ Dose Max · 100.
The area under the curve following a single acute inhalation exposure in blood (AUC AcInh ) was estimated using the trapezoidal method. The elimination rate constant (β) was determined using data collected from 30 to 240 s using the equation:
The volume of distribution (Vd AcInh ) following a single acute inhalation exposure was determined using Vd AcInh = Dose (mg)/(β · AUC AcInh ). Clearance (CL) from blood was determined using CL = β · Vd AcInh . As a confirmatory method t½ in blood was also calculated using the equation t½ = 0.693/β.
Results
During exposure all animals showed signs of intoxication manifested as sedation which began at about 20 s and rapidly progressed to more profound intoxication. At the end of the exposure period animals were prostrate and had lost all righting reflex. Animals remained visibly intoxicated until about 4 min as evidenced by either an absence of ambulation or staggered gait. From 4 to 8 min, animals showed signs of sedation in the form of reduced aggression and excitement during handling. Recovery was rapid, and at 8 min post exposure, animals showed no signs of obvious intoxication.
Point to point plots of all tissue results are presented in (Figure 2 ). Individual tissue data following nonlinear analysis of time versus concentration, plotted both standard and logarithmically (log C) are presented in (Figure 3A-3J ). Correlation analysis expressed as r 2 was 0.9329, 0.9571, 0.9371, 0.8393, and 0.9060 for blood, brain, heart, liver, and kidney, respectively. The graphed results of log C versus concentration produced curved lines characteristic of compounds that exhibit multicompartment toxicokinetics. Of particular interest was the relative concentration of DFE in the target tissues, brain, and heart so these tissues were graphed together as shown in (Figure 4) .
The results from regression analysis (data not shown) of blood, brain, and heart were used to calculate t ½ during the distribution and elimination phases. The initial distribution phase (α) for blood, brain, and heart was much shorter than either of the other elimination phases. As a consequence only a single point could be calculated starting at t 0 . The half time of all calculated specimen results in the various phases of distribution and elimination are summarized in Table I . Dose Max for 320-g male SD rats was estimated to be 283 mg (283,000 μg). Total tissue burdens were calculated by multiplying the tissue concentration at t 0 by the estimated tissue weight. Total body burden from these compartments = 11,316 μg. Total percent uptake = 11,316 μg/283,000 μg · 100 = 4.0%. Percent uptake of individual compartments was calculated by dividing individual tissue burden by the calculated total dose. Results are shown in Table II Table III .
Discussion
Given that, in 2005, over 25% of reported inhalant abuse involved misuse of duster products, research into DFE toxicology is needed. DFE has been described as practically nontoxic (21), and when used as intended, it poses little risk of adverse outcome. Unfortunately, DFE-containing products have been diverted from their original intended use, and DFE has become a substance of abuse. When abused, substantially greater exposure to DFE occurs, and as a result, this volatile gas has entered the arena of medicolegal investigation.
Toxicokinetic parameters for DFE are unreported (21) . The studies into DFE toxicology have focused primarily on DFE toxicodynamics and have not correlated response to tissue levels. This research set out to determine some of the fundamental kinetic parameters using a protocol mimicking DFE abuse, an experimental design that has not been attempted. The protocol allowed for the in vivo determination DFE during the distribution and elimination phases and for the reasonable estimation of bioavailability. Tissue plots of log concentration versus time from 0 to 900 s resulted in curved lines typical of compounds that distribute according to a multi compartment toxicokinetic model (25) .
Inhaled, DFE is unlikely to be significantly absorbed in either the nasopharyngeal region or the trachea, even in obligatory nose breathers like the rat, because of its low solubility in water (0.017 g/mL) (21) . As a result the majority of DFE absorption likely occurs in the alveoli, where it equilibrates with the blood of the pulmonary capillaries. With a favorable concentration gradient, DFE diffuses into blood and is distributed. Distribution of gases like DFE are limited by the perfusion and solubility in the various tissues (29) . Accordingly, a physiologically based toxicokinetic (PBTK) model developed for 1,1,1,2-tetrafluoroethane found that inhalation uptake was still 2-3% 2 h after initiation of exposure due to continued uptake into adipose (30) . Considering the much shorter time of DFE exposure used here (30 s), poorly perfused tissues like adipose are unlikely to have accumulated substantial DFE levels. Multiple doses of DFE are typical in abuse and are likely to increase DFE body burden due to continued uptake into lowly perfused tissues.
Additional body burden would alter the toxicokinetic parameters determined in this experiment. Vd and other toxicokinetic data are ideally determined using bolus amounts of drug or chemical administered instantaneously via intra venous injection. In addition, DFE is rapidly eliminated by exhalation. Therefore, the Vd derived here from acute exposure (0.06 L) using AUC as a measure of blood concentration may underestimate DFE kinetic parameters associated with chronic use. Calculating the initial volume of distribution using blood concentration at t 0 and animal weight provided an estimated Vd = 0.10 L/kg (range 0.08-0.12) compared to 0.06 L which was determined using AUC. Further experiments are required to assess the impact multiple doses would have on distribution and elimination.
After cessation of DFE exposure, the animals remained visibly intoxicated until about 4 min, and blood levels averaged 21 mg/L. Two reports of fatal MVA involving DFE intoxication reported blood levels of 29.8 and 78 mg/L (9,10) which correlate well to the observed effects of DFE intoxication in this study. During the period from about 4-8 min, animals remained sedated, then recovered quickly at about 8 min when blood levels had fallen to 10 mg/L.
Adult exposure following a single dose of DFE can be estimated by multiplying the concentration of DFE at 1 atm (2.7 g/L) by lung capacity 6 L (31). Using this calculation, an estimated 16.2 g of DFE may be inhaled in a single dose, equivalent to 0.231 mg/g for a 70 kg individual. In contrast the estimated maximum DFE dose in this study was 283 mg or 0.884 mg/g in 320-g rats. The aforementioned body burden calculations assume 100% absorption but the actual bioavailability of inhaled DFE and other gases are much less than 100%. The uptake of the structurally similar compound 1,1,1,2-tetrafluoroethane was estimated to be 3.7% (30) and only 1.6% for inhaled 1,1,1-trifluoroethane (32), however both of these reports had to rely on estimated tissue partition coefficients for toxicokinetic modeling because true coefficients were unavailable. From this research, the uptake of DFE from a single dose was estimated to be 4.0%. Therefore, given a 16.2-g dose and the apparent bioavailability, the uptake in grams in human adults is approximated to be 0.648 g.
The % uptake into blood in the rat was 2.7%. Assuming a 16.2-g dose, similar uptake and the blood volume of human adults (5 L), the estimated human blood concentration would be 87.5 mg/L. Remarkably the blood concentration in rats was highly correlated to this estimation for human subjects. The experimentally determined rat blood peak concentration was about four times higher (352 mg/L) than the calculated estimation of peak blood concentration in humans (87.5 mg/L). The rats however received a dose that on a mg/g basis is also estimated to be nearly four times greater than the estimated human dose (0.231 mg/g human vs. 0.884 mg/g rat).
Documented human exposures have been reported (33) . The blood estimate of 87.5 mg/L is in agreement with some of the reported cases. Other blood results, however, have been higher (> 300 mg/L). Possible explanations are that multiple doses were taken prior to death or that the direct consumption and the forcible holding of breath during exposure caused DFE pressure to be higher than 1 atm. Higher pressures result in lung concentrations greater than the assumed 2.7 g/L subjecting individuals to the concentration effect as described by Wollman and Dripps (34) . Combined with high pressure this condition would more effectively drive DFE into the blood.
Brain levels were highest at t 0 and at peak, were highest of all tissues analyzed. Even though brain levels were at least 167 mg/(L or kg) higher than any other measured tissue at peak, by 60 s concentrations had dropped below all others and remained lower until the final group when all tissues approached unity. This finding is similar to that observed for toluene where clearance from mouse brain was most rapid of all measured tissues (35) . Rapid clearance from brain is unexpected when considering the lipophilicity of many abused inhalants and the brains limited capacity for metabolism. This phenomenon has been explained by the high perfusion rate of the brain (750 mL/min) (36) .
CNS effects were profound at t 0 and visible intoxication lasted until approximately 4 min when brain DFE levels were 17-18 mg/kg. Sedation lasted until about 8 min, when brain DFE levels were about 6 mg/kg. One case study that reported brain DFE levels after fatal MVA and intoxication appeared to be a factor in the crash found DFE brain levels of 11.7 mg/kg (9) . Similar DFE levels occurred in rats at 5.5 min using this protocol, a point where animals were still showing signs of sedation. In another unreported case involving intoxication (unpublished data) leading to fatal MVA, brain levels were 55.2 mg/kg. An uninvolved motorist observed the deceased driving erratically at a high rate of speed. During this study similar brain concentrations occurred in the animals at about 1 min and 15 s after withdrawal of DFE exposure, a time when animals were still showing gross signs of intoxication.
Heart DFE levels following DFE exposure are unreported. The study protocol employed here allowed heart DFE levels to be simultaneously determined along with other tissues. Previous reports (33, 37) speculated that if DFE elimination proceeded more rapidly in brain versus heart, then abusers might re-dose as CNS effects wore off while cardiac tissue levels remained high. Multiple doses of DFE might then lead to the accumulation of DFE in cardiac tissue. In this experiment, DFE levels in cardiac tissue were reduced by half at a rate 9 s slower than brain during the α phase (27 vs. 18 s), and t ½ was nearly a minute longer (168 vs. 110 s) in heart versus brain during β elimination. Consequently, heart levels did remain higher than brain tissue after about 60 s post DFE withdrawal. The relationship between the relative amounts of DFE in these target tissues can be clearly seen in Figure 4 . This is the first evidence that DFE levels in cardiac tissue are higher than brain following abuse at a time when CNS effects are subsiding. Volatile toxins have been shown to act through specific targets but that evidence does not negate the possibility that high levels of DFE cause adverse effects on membrane integrity and accumulation of DFE within membranes may be critical to the development of toxic effects. Supportive evidence is found in one unpublished case of apparent intentional overdose using DFE where cardiac tissue contained 492.4 mg/kg and brain contained 224.1 mg/kg (unpublished data).
DFE levels in liver peaked 10 s after cessation of exposure (187 mg/kg), the only tissue in which this occurred. Following inhalation exposure dissolved gases are initially only supplied to the liver through the hepatic artery. Blood flow to the liver via the hepatic artery occurs after passing through the lipid rich brain. Liver DFE levels peaked lowest of all measured tissues and had the second lowest concentrations after 60 s, following brain, throughout the 15 min duration of the study. The observed levels probably reflect these physiologic factors.
DFE and similar compounds are expected to be only sparingly metabolized (< 1%), (38) and the majority of elimination occurs by exhalation of gas through the lungs. A proposed mechanism of DFE oxidation (39) in part proceeds through CYP-2E1 forming intermediate aldehydic metabolites. It has been suggested that as fluoride substitution increases in hydrofluorocarbons, there is an increase in the accumulation of aldehyde metabolites due to a decrease in alcohol dehydrogenase activity (40) .
The accumulation of an electrophillic species capable of covalently binding cellular macromolecules could reasonably be argued to provide a mechanism for DFE toxicity. However, chronic dosing studies have not shown evidence of hepatic fibrosis or other organ damage that could be related to accumulation of aldehydic products of DFE metabolism (21) . Nevertheless the levels of exposure to DFE as seen during abuse were largely unanticipated by manufacturers and researchers and toxic metabolites may yet prove to be problematic to heavy abusers. In fact, in one two-year study where rats were exposed to DFE doses 6 h/day, 5 day/week, there was a dosedependent increase in urinary fluoride suggestive of DFE metabolism (21) .
Kidney DFE peak concentrations (364 mg/kg) were observed at t 0 and were similar in magnitude to those seen in blood and heart. Kidney DFE concentrations were higher than all other measured tissues from about 130 s until the end of the study. In fact kidney DFE levels were twice that of the next highest tissue (heart 15, kidney 32) at 480 s and are estimated by regression analysis to be almost 3 times higher than heart at about 12 min. This observation could mean that kidney is susceptible to DFE accumulation. In addition aliphatic hydroxylation of DFE to hydrophilic alcohols and subsequent formation aldehydic species could uniquely predispose kidney to DFE toxicity but again, no statistically significant lesions in kidney were observed in chronic dosing studies (21) .
A single 10-oz canister contains 283.5 g of DFE. Using the toxicokinetic calculations determined in this research, one canister holds enough gas for almost 18 "hits" of inhalant in a fully developed adult. Based upon the observations of the intoxicated animals used in this research, one could speculate that, to maintain intoxication, an abusing individual would re-dose approximately every 10 min, and therefore, one canister contains enough DFE for 3 h of intoxication. Using this scenario, it is likely that minimally perfused tissue compartments would continuously uptake DFE, and chronic abusers may therefore have slower elimination rates and experience longer lasting effects when compared to acute abusers. Additional studies are required to verify if continued accumulation of DFE in heart versus brain occurs after multiple doses as is suggested by this research.
Conclusions
Using the animal exposure protocol and data presented, the author's successfully calculated some standard toxicokinetic parameters following acute exposure to DFE. The dose was selected to mimic exposure during intentional abuse, a protocol which has previously not been reported. Measured animal tissue results were correlated to the observed effects and were compared to results from medical examiner case work providing a basis for interpreting DFE tissue levels. In addition this experiment found that DFE levels in cardiac tissue remained higher than those in brain at a time when the intoxicating effects were subsiding. This finding suggests that DFE may accumulate in cardiac tissue with repeated exposure during abuse.
